2,247
Participants
Start Date
March 29, 2021
Primary Completion Date
December 31, 2024
Study Completion Date
February 28, 2025
First antenatal care + test-of-cure
Single point-in-time molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and infection-specific test-of-cure 3 weeks post-treatment. Women with a positive test-of-cure will be re-treated. As CT/NG is a combined Xpert test, women who present with an incident infection (newly diagnosed infection) will be treated and managed accordingly.
First antenatal care + week 30-34 gestation (no test-of-cure)
Repeated molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and at week 30-34 gestation. No test-of-cure will be conducted for women with positive test results; however, additional treatment will be provided to women with persistent/recurrent vaginal discharge.
Buffalo City Metro, East London
University of Southern California
OTHER
National Institutes of Health (NIH)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
University of Cape Town
OTHER
University of Alabama at Birmingham
OTHER
Louisiana State University Health Sciences Center in New Orleans
OTHER
Foundation for Professional Development (Pty) Ltd
OTHER